News
-
Dutch inhaled drug developer PureIMS said that it has initiated a Phase 1 clinical trial of its Amikacin Cyclops DPI, which it is developing for the treatment of drug susceptible tuberculosis. The single ascending dose… Read more . . .
-
Orexo has announced that a Phase 1 bioavailability study of three formulations of its OX125 intranasal nalmefene compared to intramuscular nalmefene injection showed that all three were well tolerated and well absorbed. Orexo is developing… Read more . . .
-
The Japanese Ministry of Health, Labour and Welfare has approved two Novartis DPIs — Enerzair Breezhaler glycopyrronium / indacaterol/ mometasone furoate and Atectura indacaterol / mometasone furoate — for the treatment of asthma, the company… Read more . . .
-
Meissa Vaccines has provided updates on two intranasal live attenuated vaccines (LAVs) based on its “codon deoptimized RSV vaccine platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines.” The company said that… Read more . . .
-
Over a dozen well-known OINDP specialists have issued a call for accelerated development of inhaled therapies for COVID-19, with the goal of getting these products to patients faster. Writing to the editor of the Journal… Read more . . .
-
Tiziana Life Sciences has announced a new agreement with STC Biologics for manufacturing of its TZLS-501 inhaled anti-IL-6 receptor monoclonal antibody. The company said that it is also working with Sciarra Laboratories to develop a… Read more . . .
-
Propellant manufacturer Koura (formerly Mexichem) has announced a “multimillion-pound sterling investment” in a new cGMP production facility for Zephex HFA 152a medical propellant at the company’s Runcorn, UK location. The new facility is expected to… Read more . . .
-
TFF Pharmaceuticals has announced topline safety results from a Phase 1 trial of its inhaled dry powder voriconazole, which is in development for the treatment of invasive pulmonary aspergillosis. The study demonstrated that doses as… Read more . . .
-
Inhaled drug developer Senzer has announced major changes to its management “aimed at bolstering its commercialization strategy for COVID-19 and cannabinoid treatments.” In May 2020, Senzer announced that it was developing two inhaled anti-virals delivered… Read more . . .
-
AstraZeneca said that complete results from the Phase 3 ETHOS trial of its Breztri Aerosphere (PT010) budesonide/glycopyrronium/formoterol fumarate MDI demonstrated that the triple combination reduced moderate or severe COPD exacerbations by 24% compared to glycopyrronium/formoterol… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.